NAUTILUS BIOTECHNOLOGY INC
NASDAQ: NAUT (Nautilus Biotechnology, Inc.)
Last update: 13 minutes ago1.20
-0.46 (-27.71%)
| Previous Close | 1.66 |
| Open | 1.60 |
| Volume | 2,109,735 |
| Avg. Volume (3M) | 716,183 |
| Market Cap | 152,494,640 |
| Price / Book | 1.49 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -0.540 |
| Total Debt/Equity (MRQ) | 15.09% |
| Current Ratio (MRQ) | 17.36 |
| Operating Cash Flow (TTM) | -56.82 M |
| Levered Free Cash Flow (TTM) | -34.19 M |
| Return on Assets (TTM) | -19.06% |
| Return on Equity (TTM) | -30.93% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Nautilus Biotechnology, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | -0.67 |
|
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 33.38% |
| % Held by Institutions | 48.76% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| A16z Capital Management, L.L.C. | 31 Mar 2026 | 17,653,917 |
| Cercano Management Llc | 31 Mar 2026 | 7,172,985 |
| Madrona Venture Group, Llc | 31 Dec 2025 | 6,020,770 |
| Clarius Group, Llc | 31 Dec 2025 | 1,209,646 |
| Sentinel Trust Co Lba | 30 Jun 2026 | 750,000 |
| Tikvah Management Llc | 31 Mar 2026 | 726,895 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |